CORT - Corcept Therapeutics - Stock & Dividends

Corcept Therapeutics Incorporated is a biopharmaceutical company that focuses on developing innovative treatments for severe and rare diseases. The company's primary objective is to improve the lives of patients suffering from endocrinologic, oncologic, metabolic, and neurologic disorders.

One of Corcept's flagship products is Korlym, a medication approved by the FDA for treating hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome. This medication is specifically designed for patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Corcept's pipeline is robust, with several promising candidates in various stages of clinical trials. Relacorilant, a potential treatment for Cushing's syndrome, is currently in phase III clinical trial. The company is also exploring relacorilant's potential in treating adrenal cancer and cortisol excess, which is in phase 1b clinical trial, as well as prostate cancer, which is in phase II clinical trial. Additionally, Corcept is investigating the combination of nab-paclitaxel with relacorilant to treat platinum-resistant ovarian tumors, which is in phase III clinical trial.

Furthermore, Corcept is developing dazucorilant, a potential treatment for amyotrophic lateral sclerosis (ALS), which is in phase II clinical trial. The company is also working on miricorilant, a potential treatment for nonalcoholic steatohepatitis (NASH), which is in phase IIb trial. Another area of focus is the treatment of antipsychotic-induced weight gain, which is in phase I trial.

Founded in 1998, Corcept Therapeutics is headquartered in Menlo Park, California, and is committed to advancing its pipeline of innovative therapies to address significant unmet medical needs. For more information, please visit their website at https://www.corcept.com.